Carmell Therapeutics (CTCX) - Long-Term Debt to Capital Coefficient
Carmell Corporation (CTCX) automates the creation of plasma matrices through AI and robotics, minimizing human error. Serving as a valuation tool, this price chart shows the metric at 0.00. Business growth relies on wound healing and orthopedic innovations. At the same time, the company lacks stable revenue streams, as its biotech projects are only now entering the market, and viability is maintained through legacy investments.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_CTCX_-_Carmell-Corporation_-_Long-Term-Debt-to-Capital "CTCX: Carmell Long-Term Debt to Capital 02/21/2024 - 03/10/2025 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Carmell Corporation (CTCX)
Carmell Corporation (CTCX) is actively transforming its business model, focusing on the commercialization of bioactive cosmetic systems. This indicator captures the ratio of debt with a maturity of over one year to equity. Analyzing the long-term debt-to-equity ratio allows for an assessment of financial leverage and the risks of underinvestment in development. Current debt levels appear moderate against the backdrop of past losses already priced in. This confirms the fundamental stability of the stock's valuation.